Dacomitinib (PF-00299804) drate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib drate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC).
References:
[1]. Lau SCM, et al. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Drugs. 2019 Jun;79(8):823-831.
















